The value of measuring ANCA during follow-up to predict a relapse is controversial. On the basis of recently obtained pathophysiologic insights, we postulated that measuring ANCA is useful in patients with renal involvement but is less valuable in patients with nonrenal disease. One hundred sixty-six consecutive patients with ANCA-associated vasculitis, positive for either proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA, were included in our study, followed at regular intervals, and tested for PR3-ANCA and MPO-ANCA. In this cohort, 104 patients had renal involvement (72 with PR3-ANCA, 32 with MPO-ANCA) and 62 patients had nonrenal disease (36 with PR3-ANCA, 26 with MPO-ANCA). During an average (6SD) follow-up of 49633 months and 18614 ANCA measurements, 89 ANCA rises and 74 relapses were recorded. ANCA rises correlated with relapses in patients who presented with renal involvement (hazard ratio [HR], 11.09; 95% confidence interval [95% CI], 5.01 to 24.55), but in comparison, associated only weakly with relapses in patients who presented with nonrenal disease (HR, 2.79; 95% CI, 1.30 to 5.98). In conclusion, longitudinal ANCA measurements may be useful in patients with renal involvement but is less valuable in patients with nonrenal disease.
ANCAs play an important role in the pathophysiology of ANCA-associated vasculitis (AAV). 1 The value of measuring ANCA to predict disease activity, however, is controversial. [2] [3] [4] [5] A recent meta-analysis calculated a pooled positive likelihood ratio of 2.8 (95% confidence interval [95% CI], 1.7 to 4.9), concluding that serial ANCA measurements are of limited value. 5 However, the interpretation of this meta-analysis is difficult because the published studies are very heterogeneous and prospective and retrospective studies are lumped together. On the basis of pathophysiologic insights, 1 we hypothesize that serially measuring ANCA is useful in patients with renal involvement but is less valuable in patients with nonrenal disease. It was previously demonstrated that ANCAs induce GN but require more modification to induce granulomatous lesions in mouse models. 6 Furthermore, ANCA is nearly always found in patients with renal involvement, whereas a subgroup of patients with nonrenal disease are clearly ANCA negative. 3, 7 Therefore, we investigated the relationship of an ANCA rise with a relapse in our cohort and divided our patients into those with and without renal involvement.
Between January 1, 2000, and November 1, 2011, 201 patients visited our university hospital with a diagnosis of AAV 8 and were positive for either myeloperoxidase (MPO)-ANCA or proteinase 3 (PR3)-ANCA. 9 Twenty-eight patients were excluded because we could not obtain follow-up data. Seven patients were refractory to treatment and did not reach stable clinical remission; these patients were also excluded. Of the remaining 166 patients, 74 patients (44.6%) did not experience a relapse during an average (6SD) follow-up of 7.565.9 years. All other patients had one or more relapses. There were 1, 2, 3, 4, or 5 relapses in 42 (25.3%), 31 (18.7%), 7 (4.2%), 4 (2.4%), and 8 (4.8%) patients, respectively. The relapse frequency was on average 0.1760.21 per year for patients with PR3-ANCA and 0.1160.18 for patients with MPO-ANCA (P=0.06).
To study the association of an ANCA rise with a relapse, the 166 patients were included when they entered their first remission after visiting our hospital. This study included 126 patients (75.9%) during remission after diagnosis and 40 patients during remission after a relapse. At the time of relapse, all 26 patients with a major relapse were ANCA positive. In 24 patients (92%), the relapse was preceded by an ANCA rise. By contrast, only 32 of 48 patients (67%) with a minor relapse were ANCA positive at the time of relapse. In addition, the relapse was preceded by an ANCA rise in only 28 patients (58%). In patients who became ANCA negative during follow-up, all major relapses were preceded by an ANCA rise ( Figure 1 ).
In the entire cohort, an ANCA rise is significantly associated with a relapse (hazard ratio [HR], 5.84; 95% CI, 3.44 to 9.92; P,0.001). A rise is strongly related to a relapse in patients with renal involvement (HR, 11.09; 95% CI, 5.01 to 24.55; P,0.001), whereas an ANCA rise is only weakly associated with a relapse in patients with nonrenal disease (HR, 2.79; 95% CI, 1.30 to 5.98; P=0.01). In addition, a rise is strongly associated with a relapse in patients with nonrenal severe 10 disease (four relapses in 16 patients; HR, 13.08; 95% CI, 1.03 to 166.7; P=0.04), but not in patients with nonrenal limited 10 disease (26 relapses in 46 patients; HR, 2.09; 95% CI, 0.92 to 4.78; P=0.08). Sampling interval (categorized as $4 measurements per year or fewer) and ANCA pattern (categorized as persistently ANCA positive or not) were additional factors that influenced the relationship of an ANCA rise with a relapse (Figure 2 , Supplemental Material).
How can our results be translated to daily practice? First, in patients who became ANCA negative during followup, the risk of developing a major relapse was extremely low as long as no rise in ANCA level occurred. Second, an ANCA rise in a patient with previous renal involvement should warn the clinician of a relapse because the probability of a relapse occurring after the rise is .11 times higher compared with the period before the rise. Third, measuring serial ANCA levels in patients without renal involvement, especially when severe vasculitic manifestations are lacking, is of limited value. 11 However, an ANCA rise should not be used to preemptively treat the patient, 12,13 because only less than one-half of the patients with an ANCA rise will experience a relapse within a year. Serial ANCA measurement is an important factor, but is not the only factor that should be considered during follow-up in patients with AAV. 14, 15 In 2006, a meta-analysis on the value of ANCA measurements to predict relapses concluded that no firm conclusions could be drawn because of considerable methodologic heterogeneity in the different studies. 4 By contrast, another metaanalysis based on a more selected subgroup of these studies concluded that serial ANCA measurements have limited use. 5 We found that the proportion of patients with renal involvement dictates the conclusion regarding whether ANCA measurements are of value during follow-up. Furthermore, we found that the association of an ANCA rise with a relapse was influenced by the ANCA method (Supplemental Material), sampling interval, and persistence of ANCA. Interestingly, we did not find a difference between MPO-ANCA and PR3-ANCA as previously suggested. 5, 14, 16, 17 We analyzed the articles that were in the latest meta-analysis and specified the study-level variables that may have influenced the results ( Table 2) . 5 Studies with a high prevalence of renal or "severe" disease 10 tended to have higher likelihood ratios, although variation in other studylevel variables such as the ANCA method used or the definition of an ANCA rise may obscure this association. This suggests that spectrum bias is involved. 18 The presence of ANCA is not the only factor required for disease reactivation, because many rises are not followed by a relapse. 2, 15, 19 This suggests that other qualities, such as epitope specificity and the sialylation ratio, may determine the pathogenicity of ANCA. 3, 20, 21 Otherwise, the association may be stronger when newer-generation ANCA methods are used. 3, 9, 22 Finally, a second hit may be required after the occurrence of an ANCA rise before the patient truly develops a relapse. The importance of a second hit was previously demonstrated in a mouse model of MPO-ANCA, 23 but remains elusive in humans. Possible candidates are microorganisms, 24 environmental factors, 25, 26 and/or other autoantibodies. 27 Our study has several limitations. In daily practice, 2, 19 the time between ANCA measurements varies, as was found in our study. We resolved this issue by using the slope of a rise, thereby taking into account the time between measurements. In this study, physicians were not blinded to ANCA results, 2, 19 which could have had an effect on diagnosing relapses. This may have influenced the association between an ANCA rise and a relapse in the entire cohort, but could not explain the marked difference between patients with and without renal involvement. A minority of patients suffered from microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis, making any conclusion on ANCA testing in these diseases less valid. Renal involvement may be a proxy for severe vasculitic disease because we found that an ANCA rise in patients with severe nonrenal disease was also associated with a relapse in this small subgroup of patients. Finally, 5 of 62 patients who were initially diagnosed with nonrenal disease developed a renal relapse, suggesting that we should probably focus on markers of the biologic behavior of the disease in patients that initially present with nonrenal disease in order to predict the value of serial ANCA measurements in this patient subgroup. 28 In summary, we have demonstrated in the largest published cohort with longitudinal ANCA measurements that an ANCA rise is related to a relapse in patients with renal involvement, but less in patients with nonrenal disease.
CONCISE METHODS
Renal involvement was determined by a renal biopsy showing pauci-immune necrotizing GN. 29 However, the presence of hematuria in combination with red cell casts, dysmorphic erythrocytes (.10), and/or proteinuria sufficed (a renal biopsy was not performed in 12 patients with renal involvement). 30 Disease activity was scored using the Birmingham Vasculitis Activity Score (version 3). 31 Patients were treated according to the European League Against Rheumatism guidelines as previously described. 29 Maintenance therapy was given for at least 18 months and tapered within 24 months according to protocol in newly diagnosed patients. 32 Patients who previously relapsed and/or relapsed during our study while using maintenance therapy were offered long-term maintenance therapy. Remission was defined as the absence of disease activity attributable to active disease during maintenance immunosuppressive therapy of a prednisone dose #7.5 mg. 33 A relapse was defined as the reoccurrence or new onset of disease attributable to active disease combined with an increase or addition of immunosuppressive treatment. 12, 19, 32, 33 Relapses were further subdivided into minor or major relapses, depending on whether the relapse was potentially organ-or lifethreatening. 33 For a renal relapse, the (re) occurrence of hematuria in combination with a rise in serum creatinine of 25% was required to be characterized as a major relapse.
Solid-phase ANCA tests were used to detect and quantify PR3-ANCA and MPO-ANCA (Supplemental Material). 3, 9 For quantitation of MPO-ANCA and PR3-ANCA, the samples were diluted 1:50 in PBS as instructed by the manufacturer. Results were calculated in arbitrary units by a standard curve. Patient samples with results above the highest standard were further tested in 2-fold dilutions as appropriate. For the detection of an ANCA rise, the ANCA value was compared with the value measured in the samples obtained in the 6 months before the current sample. We defined a rise using the slope of an increase, for which a receiver operating characteristic curve was calculated to determine the optimal cut-off value (Supplemental Material). 19 The association between an ANCA rise and relapse was investigated using a Cox regression model with an ANCA rise included as a time-dependent, binary, nonreversible predictor. 19, 34 
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